Name: XOMA ROYALTY CORPORATION (XOMA) Stock
Brand: XOMA ROYALTY CORPORATION
Rating: 4.5 (3 reviews)

XOMA Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: XOMA Royalty Corporation

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

3 days ago - By: XOMA Royalty Corporation - Mentions: LVTX

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

12 days ago - By: Zacks Investment Research - Mentions: VTGN

XOMA Royalty (XOMA) Reports Q3 Loss, Lags Revenue Estimates

12 days ago - By: Zacks Investment Research - Mentions: TCRX

TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates

2 months ago - By: Stocktwits - Mentions: LVTX

LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting

2 months ago - By: ESSA Pharma Inc. - Mentions: EPIX

ESSA Pharma Inc. Amends Agreement with XenoTherapeutics

3 months ago - By: Stocktwits - Mentions: MURA

Mural Oncology To Be Acquired By Xoma Royalty

12 days ago - By: XOMA Royalty Corporation

XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

12 days ago - By: XOMA Royalty Corporation

XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

20 days ago - By: Zacks Investment Research - Mentions: TNGX

Tango Therapeutics, Inc. (TNGX) Tops Q3 Earnings and Revenue Estimates

a month ago - By: Mural Oncology plc - Mentions: MURA

Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty

3 months ago - By: The Motley Fool

XOMA Revenue Jumps 39% in Fiscal Q2

4 months ago - By: Rowley Law PLLC - Mentions: HLVX

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.

a month ago - By: Zacks Investment Research - Mentions: UNH GS PSA MU ...

Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus

a month ago - By: Stocktwits - Mentions: LVTX

LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty

a month ago - By: XOMA Royalty Corporation; LAVA Therapeutics N.V.

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

a month ago - By: XOMA Royalty Corporation; LAVA Therapeutics N.V. - Mentions: LVTX

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

2 months ago - By: XOMA Royalty Corporation; LAVA Therapeutics - Mentions: LVTX

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

2 months ago - By: XOMA Royalty Corporation; LAVA Therapeutics

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

2 months ago - By: XOMA Royalty Corporation

XOMA Royalty Declares Quarterly Preferred Stock Dividends

2 months ago - By: XOMA Royalty Corporation

XOMA Royalty Declares Quarterly Preferred Stock Dividends

2 months ago - By: XOMA Royalty Corporation

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

2 months ago - By: XOMA Royalty Corporation - Mentions: HLVX

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

3 months ago - By: Zacks Investment Research

Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should Know

3 months ago - By: XOMA Royalty Corporation

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: XOMA Royalty Corporation

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: Zacks Investment Research

Here's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock Now

3 months ago - By: XOMA Royalty Corporation

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

3 months ago - By: Kahn Swick & Foti, LLC - Mentions: HLVX

HILLEVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

3 months ago - By: Zacks Investment Research

How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%

3 months ago - By: Zacks Investment Research - Mentions: HOWL

XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates

3 months ago - By: XOMA Royalty Corporation

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

3 months ago - By: XOMA Royalty Corporation

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

3 months ago - By: XOMA Royalty Corporation

XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

3 months ago - By: XOMA Royalty Corporation - Mentions: TSBX

XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

4 months ago - By: Zacks Investment Research - Mentions: PTCT

PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: NVAX

Novavax (NVAX) Q2 Earnings and Revenues Top Estimates

4 months ago - By: Brodsky & Smith LLC - Mentions: HLVX SCS LVTX RKDA ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)

XOMA ROYALTY CORPORATION (XOMA) Stock News

XOMA Latest News, Press Relases and Analysis